nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluoxetine—Bromodiphenhydramine—Tamoxifen—pancreatic cancer	0.167	0.56	CrCrCtD
Fluoxetine—Orphenadrine—Tamoxifen—pancreatic cancer	0.131	0.44	CrCrCtD
Fluoxetine—SIGMAR1—Tamoxifen—pancreatic cancer	0.0838	0.169	CbGbCtD
Fluoxetine—ORM1—Erlotinib—pancreatic cancer	0.0449	0.0905	CbGbCtD
Fluoxetine—CYP2B6—Tamoxifen—pancreatic cancer	0.0227	0.0457	CbGbCtD
Fluoxetine—ALB—Erlotinib—pancreatic cancer	0.0189	0.0381	CbGbCtD
Fluoxetine—CYP3A5—Tamoxifen—pancreatic cancer	0.0178	0.036	CbGbCtD
Fluoxetine—CYP2B6—Irinotecan—pancreatic cancer	0.0174	0.0351	CbGbCtD
Fluoxetine—ALB—Irinotecan—pancreatic cancer	0.017	0.0344	CbGbCtD
Fluoxetine—CYP1A2—Dacarbazine—pancreatic cancer	0.0167	0.0337	CbGbCtD
Fluoxetine—ALB—Fluorouracil—pancreatic cancer	0.0164	0.033	CbGbCtD
Fluoxetine—CYP3A5—Erlotinib—pancreatic cancer	0.0152	0.0306	CbGbCtD
Fluoxetine—CYP2C19—Tamoxifen—pancreatic cancer	0.0144	0.029	CbGbCtD
Fluoxetine—CYP3A5—Irinotecan—pancreatic cancer	0.0137	0.0276	CbGbCtD
Fluoxetine—CYP1A2—Tamoxifen—pancreatic cancer	0.0133	0.0268	CbGbCtD
Fluoxetine—CYP2C9—Tamoxifen—pancreatic cancer	0.012	0.0241	CbGbCtD
Fluoxetine—ABCB1—Tamoxifen—pancreatic cancer	0.0116	0.0234	CbGbCtD
Fluoxetine—CYP1A2—Erlotinib—pancreatic cancer	0.0113	0.0228	CbGbCtD
Fluoxetine—CYP2D6—Tamoxifen—pancreatic cancer	0.0109	0.0221	CbGbCtD
Fluoxetine—CYP3A5—Docetaxel—pancreatic cancer	0.01	0.0203	CbGbCtD
Fluoxetine—ABCB1—Gemcitabine—pancreatic cancer	0.01	0.0202	CbGbCtD
Fluoxetine—CYP3A5—Sunitinib—pancreatic cancer	0.01	0.0202	CbGbCtD
Fluoxetine—ABCB1—Erlotinib—pancreatic cancer	0.00988	0.0199	CbGbCtD
Fluoxetine—CYP1A2—Fluorouracil—pancreatic cancer	0.00979	0.0197	CbGbCtD
Fluoxetine—CYP2B6—Doxorubicin—pancreatic cancer	0.0095	0.0192	CbGbCtD
Fluoxetine—CYP2D6—Erlotinib—pancreatic cancer	0.0093	0.0188	CbGbCtD
Fluoxetine—ABCB1—Irinotecan—pancreatic cancer	0.00892	0.018	CbGbCtD
Fluoxetine—CYP2C9—Fluorouracil—pancreatic cancer	0.00882	0.0178	CbGbCtD
Fluoxetine—CYP3A4—Tamoxifen—pancreatic cancer	0.00696	0.014	CbGbCtD
Fluoxetine—ABCB1—Docetaxel—pancreatic cancer	0.00654	0.0132	CbGbCtD
Fluoxetine—ABCB1—Sunitinib—pancreatic cancer	0.00651	0.0131	CbGbCtD
Fluoxetine—CYP3A4—Erlotinib—pancreatic cancer	0.00592	0.0119	CbGbCtD
Fluoxetine—CYP3A4—Irinotecan—pancreatic cancer	0.00534	0.0108	CbGbCtD
Fluoxetine—ABCB1—Doxorubicin—pancreatic cancer	0.00487	0.00983	CbGbCtD
Fluoxetine—CYP2D6—Doxorubicin—pancreatic cancer	0.00459	0.00926	CbGbCtD
Fluoxetine—ORM1—bile—pancreatic cancer	0.00396	0.286	CbGeAlD
Fluoxetine—CYP3A4—Docetaxel—pancreatic cancer	0.00392	0.0079	CbGbCtD
Fluoxetine—CYP3A4—Sunitinib—pancreatic cancer	0.0039	0.00786	CbGbCtD
Fluoxetine—HTR2A—enteric nervous system—pancreatic cancer	0.0034	0.246	CbGeAlD
Fluoxetine—CYP3A4—Doxorubicin—pancreatic cancer	0.00292	0.00589	CbGbCtD
Fluoxetine—ORM1—gall bladder—pancreatic cancer	0.0011	0.0795	CbGeAlD
Fluoxetine—ALB—gall bladder—pancreatic cancer	0.000964	0.0697	CbGeAlD
Fluoxetine—SIGMAR1—islet of Langerhans—pancreatic cancer	0.00061	0.0441	CbGeAlD
Fluoxetine—SIGMAR1—pancreas—pancreatic cancer	0.000429	0.031	CbGeAlD
Fluoxetine—CYP3A5—islet of Langerhans—pancreatic cancer	0.000401	0.029	CbGeAlD
Fluoxetine—SLC6A4—digestive system—pancreatic cancer	0.000369	0.0267	CbGeAlD
Fluoxetine—CYP2C19—digestive system—pancreatic cancer	0.000306	0.0221	CbGeAlD
Fluoxetine—CYP3A5—pancreas—pancreatic cancer	0.000282	0.0204	CbGeAlD
Fluoxetine—CYP1A2—digestive system—pancreatic cancer	0.00025	0.018	CbGeAlD
Fluoxetine—CYP3A5—digestive system—pancreatic cancer	0.000241	0.0174	CbGeAlD
Fluoxetine—CYP2B6—digestive system—pancreatic cancer	0.000239	0.0173	CbGeAlD
Fluoxetine—CYP2C9—digestive system—pancreatic cancer	0.000237	0.0171	CbGeAlD
Fluoxetine—ABCB1—islet of Langerhans—pancreatic cancer	0.000213	0.0154	CbGeAlD
Fluoxetine—HTR2A—digestive system—pancreatic cancer	0.000195	0.0141	CbGeAlD
Fluoxetine—CYP3A4—digestive system—pancreatic cancer	0.000181	0.0131	CbGeAlD
Fluoxetine—CYP2D6—digestive system—pancreatic cancer	0.000178	0.0129	CbGeAlD
Fluoxetine—ABCB1—pancreas—pancreatic cancer	0.00015	0.0108	CbGeAlD
Fluoxetine—ABCB1—digestive system—pancreatic cancer	0.000128	0.00924	CbGeAlD
Fluoxetine—Myalgia—Docetaxel—pancreatic cancer	5.54e-05	0.000305	CcSEcCtD
Fluoxetine—Chest pain—Docetaxel—pancreatic cancer	5.54e-05	0.000305	CcSEcCtD
Fluoxetine—Arthralgia—Docetaxel—pancreatic cancer	5.54e-05	0.000305	CcSEcCtD
Fluoxetine—Nausea—Sunitinib—pancreatic cancer	5.54e-05	0.000305	CcSEcCtD
Fluoxetine—Pancytopenia—Doxorubicin—pancreatic cancer	5.54e-05	0.000304	CcSEcCtD
Fluoxetine—Renal failure—Epirubicin—pancreatic cancer	5.52e-05	0.000303	CcSEcCtD
Fluoxetine—Asthenia—Irinotecan—pancreatic cancer	5.52e-05	0.000303	CcSEcCtD
Fluoxetine—Neuropathy peripheral—Epirubicin—pancreatic cancer	5.51e-05	0.000303	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	5.51e-05	0.000302	CcSEcCtD
Fluoxetine—Jaundice—Epirubicin—pancreatic cancer	5.48e-05	0.000301	CcSEcCtD
Fluoxetine—Stomatitis—Epirubicin—pancreatic cancer	5.48e-05	0.000301	CcSEcCtD
Fluoxetine—Urinary tract infection—Epirubicin—pancreatic cancer	5.46e-05	0.0003	CcSEcCtD
Fluoxetine—Conjunctivitis—Epirubicin—pancreatic cancer	5.46e-05	0.0003	CcSEcCtD
Fluoxetine—Dysuria—Doxorubicin—pancreatic cancer	5.45e-05	0.0003	CcSEcCtD
Fluoxetine—Hypersensitivity—Fluorouracil—pancreatic cancer	5.42e-05	0.000298	CcSEcCtD
Fluoxetine—Dry mouth—Docetaxel—pancreatic cancer	5.42e-05	0.000298	CcSEcCtD
Fluoxetine—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	5.42e-05	0.000298	CcSEcCtD
Fluoxetine—Sweating—Epirubicin—pancreatic cancer	5.39e-05	0.000296	CcSEcCtD
Fluoxetine—Pollakiuria—Doxorubicin—pancreatic cancer	5.39e-05	0.000296	CcSEcCtD
Fluoxetine—Asthenia—Gemcitabine—pancreatic cancer	5.37e-05	0.000295	CcSEcCtD
Fluoxetine—Haematuria—Epirubicin—pancreatic cancer	5.36e-05	0.000294	CcSEcCtD
Fluoxetine—Confusional state—Docetaxel—pancreatic cancer	5.36e-05	0.000294	CcSEcCtD
Fluoxetine—Photosensitivity reaction—Doxorubicin—pancreatic cancer	5.32e-05	0.000292	CcSEcCtD
Fluoxetine—Anaphylactic shock—Docetaxel—pancreatic cancer	5.31e-05	0.000292	CcSEcCtD
Fluoxetine—Weight increased—Doxorubicin—pancreatic cancer	5.31e-05	0.000292	CcSEcCtD
Fluoxetine—Epistaxis—Epirubicin—pancreatic cancer	5.3e-05	0.000291	CcSEcCtD
Fluoxetine—Pruritus—Gemcitabine—pancreatic cancer	5.3e-05	0.000291	CcSEcCtD
Fluoxetine—Infection—Docetaxel—pancreatic cancer	5.28e-05	0.00029	CcSEcCtD
Fluoxetine—Weight decreased—Doxorubicin—pancreatic cancer	5.28e-05	0.00029	CcSEcCtD
Fluoxetine—Sinusitis—Epirubicin—pancreatic cancer	5.27e-05	0.00029	CcSEcCtD
Fluoxetine—Hyperglycaemia—Doxorubicin—pancreatic cancer	5.26e-05	0.000289	CcSEcCtD
Fluoxetine—Diarrhoea—Irinotecan—pancreatic cancer	5.26e-05	0.000289	CcSEcCtD
Fluoxetine—Pneumonia—Doxorubicin—pancreatic cancer	5.23e-05	0.000287	CcSEcCtD
Fluoxetine—Shock—Docetaxel—pancreatic cancer	5.23e-05	0.000287	CcSEcCtD
Fluoxetine—Pruritus—Fluorouracil—pancreatic cancer	5.21e-05	0.000286	CcSEcCtD
Fluoxetine—Thrombocytopenia—Docetaxel—pancreatic cancer	5.2e-05	0.000286	CcSEcCtD
Fluoxetine—Drowsiness—Doxorubicin—pancreatic cancer	5.2e-05	0.000286	CcSEcCtD
Fluoxetine—Tachycardia—Docetaxel—pancreatic cancer	5.19e-05	0.000285	CcSEcCtD
Fluoxetine—Skin disorder—Docetaxel—pancreatic cancer	5.16e-05	0.000284	CcSEcCtD
Fluoxetine—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	5.16e-05	0.000283	CcSEcCtD
Fluoxetine—Bradycardia—Epirubicin—pancreatic cancer	5.14e-05	0.000282	CcSEcCtD
Fluoxetine—Diarrhoea—Gemcitabine—pancreatic cancer	5.12e-05	0.000281	CcSEcCtD
Fluoxetine—Renal failure—Doxorubicin—pancreatic cancer	5.11e-05	0.000281	CcSEcCtD
Fluoxetine—Neuropathy peripheral—Doxorubicin—pancreatic cancer	5.1e-05	0.00028	CcSEcCtD
Fluoxetine—Dizziness—Irinotecan—pancreatic cancer	5.08e-05	0.000279	CcSEcCtD
Fluoxetine—Haemoglobin—Epirubicin—pancreatic cancer	5.07e-05	0.000279	CcSEcCtD
Fluoxetine—Jaundice—Doxorubicin—pancreatic cancer	5.07e-05	0.000278	CcSEcCtD
Fluoxetine—Stomatitis—Doxorubicin—pancreatic cancer	5.07e-05	0.000278	CcSEcCtD
Fluoxetine—Anorexia—Docetaxel—pancreatic cancer	5.07e-05	0.000278	CcSEcCtD
Fluoxetine—Rhinitis—Epirubicin—pancreatic cancer	5.06e-05	0.000278	CcSEcCtD
Fluoxetine—Conjunctivitis—Doxorubicin—pancreatic cancer	5.05e-05	0.000278	CcSEcCtD
Fluoxetine—Urinary tract infection—Doxorubicin—pancreatic cancer	5.05e-05	0.000278	CcSEcCtD
Fluoxetine—Haemorrhage—Epirubicin—pancreatic cancer	5.04e-05	0.000277	CcSEcCtD
Fluoxetine—Hepatitis—Epirubicin—pancreatic cancer	5.04e-05	0.000277	CcSEcCtD
Fluoxetine—Diarrhoea—Fluorouracil—pancreatic cancer	5.04e-05	0.000277	CcSEcCtD
Fluoxetine—Hypoaesthesia—Epirubicin—pancreatic cancer	5.02e-05	0.000276	CcSEcCtD
Fluoxetine—Pharyngitis—Epirubicin—pancreatic cancer	5.01e-05	0.000275	CcSEcCtD
Fluoxetine—Sweating—Doxorubicin—pancreatic cancer	4.99e-05	0.000274	CcSEcCtD
Fluoxetine—Oedema peripheral—Epirubicin—pancreatic cancer	4.97e-05	0.000273	CcSEcCtD
Fluoxetine—Hypotension—Docetaxel—pancreatic cancer	4.97e-05	0.000273	CcSEcCtD
Fluoxetine—Haematuria—Doxorubicin—pancreatic cancer	4.96e-05	0.000272	CcSEcCtD
Fluoxetine—Epistaxis—Doxorubicin—pancreatic cancer	4.9e-05	0.000269	CcSEcCtD
Fluoxetine—Vomiting—Irinotecan—pancreatic cancer	4.89e-05	0.000269	CcSEcCtD
Fluoxetine—Sinusitis—Doxorubicin—pancreatic cancer	4.88e-05	0.000268	CcSEcCtD
Fluoxetine—Dizziness—Fluorouracil—pancreatic cancer	4.87e-05	0.000267	CcSEcCtD
Fluoxetine—Visual impairment—Epirubicin—pancreatic cancer	4.86e-05	0.000267	CcSEcCtD
Fluoxetine—Rash—Irinotecan—pancreatic cancer	4.85e-05	0.000266	CcSEcCtD
Fluoxetine—Dermatitis—Irinotecan—pancreatic cancer	4.84e-05	0.000266	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	4.84e-05	0.000266	CcSEcCtD
Fluoxetine—Headache—Irinotecan—pancreatic cancer	4.82e-05	0.000265	CcSEcCtD
Fluoxetine—Insomnia—Docetaxel—pancreatic cancer	4.81e-05	0.000264	CcSEcCtD
Fluoxetine—Paraesthesia—Docetaxel—pancreatic cancer	4.77e-05	0.000262	CcSEcCtD
Fluoxetine—Erythema multiforme—Epirubicin—pancreatic cancer	4.77e-05	0.000262	CcSEcCtD
Fluoxetine—Vomiting—Gemcitabine—pancreatic cancer	4.76e-05	0.000262	CcSEcCtD
Fluoxetine—Bradycardia—Doxorubicin—pancreatic cancer	4.75e-05	0.000261	CcSEcCtD
Fluoxetine—Dyspnoea—Docetaxel—pancreatic cancer	4.74e-05	0.00026	CcSEcCtD
Fluoxetine—Somnolence—Docetaxel—pancreatic cancer	4.72e-05	0.00026	CcSEcCtD
Fluoxetine—Rash—Gemcitabine—pancreatic cancer	4.72e-05	0.000259	CcSEcCtD
Fluoxetine—Dermatitis—Gemcitabine—pancreatic cancer	4.72e-05	0.000259	CcSEcCtD
Fluoxetine—Tinnitus—Epirubicin—pancreatic cancer	4.7e-05	0.000258	CcSEcCtD
Fluoxetine—Haemoglobin—Doxorubicin—pancreatic cancer	4.69e-05	0.000258	CcSEcCtD
Fluoxetine—Headache—Gemcitabine—pancreatic cancer	4.69e-05	0.000258	CcSEcCtD
Fluoxetine—Vomiting—Fluorouracil—pancreatic cancer	4.68e-05	0.000257	CcSEcCtD
Fluoxetine—Rhinitis—Doxorubicin—pancreatic cancer	4.68e-05	0.000257	CcSEcCtD
Fluoxetine—Dyspepsia—Docetaxel—pancreatic cancer	4.68e-05	0.000257	CcSEcCtD
Fluoxetine—Hepatitis—Doxorubicin—pancreatic cancer	4.67e-05	0.000256	CcSEcCtD
Fluoxetine—Haemorrhage—Doxorubicin—pancreatic cancer	4.67e-05	0.000256	CcSEcCtD
Fluoxetine—Hypoaesthesia—Doxorubicin—pancreatic cancer	4.64e-05	0.000255	CcSEcCtD
Fluoxetine—Rash—Fluorouracil—pancreatic cancer	4.64e-05	0.000255	CcSEcCtD
Fluoxetine—Dermatitis—Fluorouracil—pancreatic cancer	4.64e-05	0.000255	CcSEcCtD
Fluoxetine—Pharyngitis—Doxorubicin—pancreatic cancer	4.63e-05	0.000255	CcSEcCtD
Fluoxetine—Decreased appetite—Docetaxel—pancreatic cancer	4.62e-05	0.000254	CcSEcCtD
Fluoxetine—Headache—Fluorouracil—pancreatic cancer	4.61e-05	0.000253	CcSEcCtD
Fluoxetine—Oedema peripheral—Doxorubicin—pancreatic cancer	4.6e-05	0.000253	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Docetaxel—pancreatic cancer	4.59e-05	0.000252	CcSEcCtD
Fluoxetine—Fatigue—Docetaxel—pancreatic cancer	4.58e-05	0.000252	CcSEcCtD
Fluoxetine—Nausea—Irinotecan—pancreatic cancer	4.57e-05	0.000251	CcSEcCtD
Fluoxetine—Constipation—Docetaxel—pancreatic cancer	4.54e-05	0.00025	CcSEcCtD
Fluoxetine—Pain—Docetaxel—pancreatic cancer	4.54e-05	0.00025	CcSEcCtD
Fluoxetine—Chills—Epirubicin—pancreatic cancer	4.53e-05	0.000249	CcSEcCtD
Fluoxetine—Arrhythmia—Epirubicin—pancreatic cancer	4.51e-05	0.000248	CcSEcCtD
Fluoxetine—Visual impairment—Doxorubicin—pancreatic cancer	4.5e-05	0.000247	CcSEcCtD
Fluoxetine—Alopecia—Epirubicin—pancreatic cancer	4.46e-05	0.000245	CcSEcCtD
Fluoxetine—Nausea—Gemcitabine—pancreatic cancer	4.45e-05	0.000244	CcSEcCtD
Fluoxetine—Mental disorder—Epirubicin—pancreatic cancer	4.42e-05	0.000243	CcSEcCtD
Fluoxetine—Erythema multiforme—Doxorubicin—pancreatic cancer	4.41e-05	0.000242	CcSEcCtD
Fluoxetine—Malnutrition—Epirubicin—pancreatic cancer	4.39e-05	0.000241	CcSEcCtD
Fluoxetine—Feeling abnormal—Docetaxel—pancreatic cancer	4.38e-05	0.000241	CcSEcCtD
Fluoxetine—Nausea—Fluorouracil—pancreatic cancer	4.37e-05	0.00024	CcSEcCtD
Fluoxetine—Tinnitus—Doxorubicin—pancreatic cancer	4.35e-05	0.000239	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Docetaxel—pancreatic cancer	4.35e-05	0.000239	CcSEcCtD
Fluoxetine—Flatulence—Epirubicin—pancreatic cancer	4.33e-05	0.000238	CcSEcCtD
Fluoxetine—Tension—Epirubicin—pancreatic cancer	4.31e-05	0.000237	CcSEcCtD
Fluoxetine—Dysgeusia—Epirubicin—pancreatic cancer	4.3e-05	0.000236	CcSEcCtD
Fluoxetine—Nervousness—Epirubicin—pancreatic cancer	4.27e-05	0.000234	CcSEcCtD
Fluoxetine—Back pain—Epirubicin—pancreatic cancer	4.25e-05	0.000233	CcSEcCtD
Fluoxetine—Muscle spasms—Epirubicin—pancreatic cancer	4.22e-05	0.000232	CcSEcCtD
Fluoxetine—Abdominal pain—Docetaxel—pancreatic cancer	4.2e-05	0.000231	CcSEcCtD
Fluoxetine—Body temperature increased—Docetaxel—pancreatic cancer	4.2e-05	0.000231	CcSEcCtD
Fluoxetine—Chills—Doxorubicin—pancreatic cancer	4.19e-05	0.00023	CcSEcCtD
Fluoxetine—Arrhythmia—Doxorubicin—pancreatic cancer	4.17e-05	0.000229	CcSEcCtD
Fluoxetine—Alopecia—Doxorubicin—pancreatic cancer	4.12e-05	0.000227	CcSEcCtD
Fluoxetine—Mental disorder—Doxorubicin—pancreatic cancer	4.09e-05	0.000225	CcSEcCtD
Fluoxetine—Ill-defined disorder—Epirubicin—pancreatic cancer	4.07e-05	0.000224	CcSEcCtD
Fluoxetine—Malnutrition—Doxorubicin—pancreatic cancer	4.06e-05	0.000223	CcSEcCtD
Fluoxetine—Anaemia—Epirubicin—pancreatic cancer	4.06e-05	0.000223	CcSEcCtD
Fluoxetine—Agitation—Epirubicin—pancreatic cancer	4.04e-05	0.000222	CcSEcCtD
Fluoxetine—Flatulence—Doxorubicin—pancreatic cancer	4e-05	0.00022	CcSEcCtD
Fluoxetine—Tension—Doxorubicin—pancreatic cancer	3.99e-05	0.000219	CcSEcCtD
Fluoxetine—Dysgeusia—Doxorubicin—pancreatic cancer	3.98e-05	0.000219	CcSEcCtD
Fluoxetine—Malaise—Epirubicin—pancreatic cancer	3.96e-05	0.000218	CcSEcCtD
Fluoxetine—Nervousness—Doxorubicin—pancreatic cancer	3.95e-05	0.000217	CcSEcCtD
Fluoxetine—Vertigo—Epirubicin—pancreatic cancer	3.95e-05	0.000217	CcSEcCtD
Fluoxetine—Syncope—Epirubicin—pancreatic cancer	3.94e-05	0.000216	CcSEcCtD
Fluoxetine—Leukopenia—Epirubicin—pancreatic cancer	3.93e-05	0.000216	CcSEcCtD
Fluoxetine—Back pain—Doxorubicin—pancreatic cancer	3.93e-05	0.000216	CcSEcCtD
Fluoxetine—Hypersensitivity—Docetaxel—pancreatic cancer	3.92e-05	0.000215	CcSEcCtD
Fluoxetine—Muscle spasms—Doxorubicin—pancreatic cancer	3.91e-05	0.000215	CcSEcCtD
Fluoxetine—Palpitations—Epirubicin—pancreatic cancer	3.88e-05	0.000213	CcSEcCtD
Fluoxetine—Loss of consciousness—Epirubicin—pancreatic cancer	3.86e-05	0.000212	CcSEcCtD
Fluoxetine—Cough—Epirubicin—pancreatic cancer	3.83e-05	0.000211	CcSEcCtD
Fluoxetine—Asthenia—Docetaxel—pancreatic cancer	3.81e-05	0.000209	CcSEcCtD
Fluoxetine—Convulsion—Epirubicin—pancreatic cancer	3.81e-05	0.000209	CcSEcCtD
Fluoxetine—Hypertension—Epirubicin—pancreatic cancer	3.79e-05	0.000208	CcSEcCtD
Fluoxetine—Ill-defined disorder—Doxorubicin—pancreatic cancer	3.77e-05	0.000207	CcSEcCtD
Fluoxetine—Pruritus—Docetaxel—pancreatic cancer	3.76e-05	0.000207	CcSEcCtD
Fluoxetine—Anaemia—Doxorubicin—pancreatic cancer	3.76e-05	0.000206	CcSEcCtD
Fluoxetine—Arthralgia—Epirubicin—pancreatic cancer	3.74e-05	0.000205	CcSEcCtD
Fluoxetine—Chest pain—Epirubicin—pancreatic cancer	3.74e-05	0.000205	CcSEcCtD
Fluoxetine—Myalgia—Epirubicin—pancreatic cancer	3.74e-05	0.000205	CcSEcCtD
Fluoxetine—Agitation—Doxorubicin—pancreatic cancer	3.73e-05	0.000205	CcSEcCtD
Fluoxetine—Anxiety—Epirubicin—pancreatic cancer	3.73e-05	0.000205	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	3.71e-05	0.000204	CcSEcCtD
Fluoxetine—Discomfort—Epirubicin—pancreatic cancer	3.69e-05	0.000203	CcSEcCtD
Fluoxetine—Malaise—Doxorubicin—pancreatic cancer	3.66e-05	0.000201	CcSEcCtD
Fluoxetine—Dry mouth—Epirubicin—pancreatic cancer	3.66e-05	0.000201	CcSEcCtD
Fluoxetine—Vertigo—Doxorubicin—pancreatic cancer	3.65e-05	0.000201	CcSEcCtD
Fluoxetine—Syncope—Doxorubicin—pancreatic cancer	3.64e-05	0.0002	CcSEcCtD
Fluoxetine—Leukopenia—Doxorubicin—pancreatic cancer	3.64e-05	0.0002	CcSEcCtD
Fluoxetine—Diarrhoea—Docetaxel—pancreatic cancer	3.64e-05	0.0002	CcSEcCtD
Fluoxetine—Confusional state—Epirubicin—pancreatic cancer	3.61e-05	0.000199	CcSEcCtD
Fluoxetine—Palpitations—Doxorubicin—pancreatic cancer	3.59e-05	0.000197	CcSEcCtD
Fluoxetine—Anaphylactic shock—Epirubicin—pancreatic cancer	3.58e-05	0.000197	CcSEcCtD
Fluoxetine—Loss of consciousness—Doxorubicin—pancreatic cancer	3.57e-05	0.000196	CcSEcCtD
Fluoxetine—Infection—Epirubicin—pancreatic cancer	3.56e-05	0.000196	CcSEcCtD
Fluoxetine—Cough—Doxorubicin—pancreatic cancer	3.55e-05	0.000195	CcSEcCtD
Fluoxetine—Shock—Epirubicin—pancreatic cancer	3.53e-05	0.000194	CcSEcCtD
Fluoxetine—Convulsion—Doxorubicin—pancreatic cancer	3.52e-05	0.000193	CcSEcCtD
Fluoxetine—Dizziness—Docetaxel—pancreatic cancer	3.51e-05	0.000193	CcSEcCtD
Fluoxetine—Thrombocytopenia—Epirubicin—pancreatic cancer	3.51e-05	0.000193	CcSEcCtD
Fluoxetine—Hypertension—Doxorubicin—pancreatic cancer	3.51e-05	0.000193	CcSEcCtD
Fluoxetine—Tachycardia—Epirubicin—pancreatic cancer	3.5e-05	0.000192	CcSEcCtD
Fluoxetine—Skin disorder—Epirubicin—pancreatic cancer	3.48e-05	0.000191	CcSEcCtD
Fluoxetine—Hyperhidrosis—Epirubicin—pancreatic cancer	3.46e-05	0.00019	CcSEcCtD
Fluoxetine—Myalgia—Doxorubicin—pancreatic cancer	3.46e-05	0.00019	CcSEcCtD
Fluoxetine—Arthralgia—Doxorubicin—pancreatic cancer	3.46e-05	0.00019	CcSEcCtD
Fluoxetine—Chest pain—Doxorubicin—pancreatic cancer	3.46e-05	0.00019	CcSEcCtD
Fluoxetine—Anxiety—Doxorubicin—pancreatic cancer	3.45e-05	0.000189	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	3.44e-05	0.000189	CcSEcCtD
Fluoxetine—Discomfort—Doxorubicin—pancreatic cancer	3.42e-05	0.000188	CcSEcCtD
Fluoxetine—Anorexia—Epirubicin—pancreatic cancer	3.42e-05	0.000188	CcSEcCtD
Fluoxetine—Dry mouth—Doxorubicin—pancreatic cancer	3.38e-05	0.000186	CcSEcCtD
Fluoxetine—Vomiting—Docetaxel—pancreatic cancer	3.38e-05	0.000186	CcSEcCtD
Fluoxetine—Rash—Docetaxel—pancreatic cancer	3.35e-05	0.000184	CcSEcCtD
Fluoxetine—Hypotension—Epirubicin—pancreatic cancer	3.35e-05	0.000184	CcSEcCtD
Fluoxetine—Dermatitis—Docetaxel—pancreatic cancer	3.35e-05	0.000184	CcSEcCtD
Fluoxetine—Confusional state—Doxorubicin—pancreatic cancer	3.34e-05	0.000184	CcSEcCtD
Fluoxetine—Headache—Docetaxel—pancreatic cancer	3.33e-05	0.000183	CcSEcCtD
Fluoxetine—Anaphylactic shock—Doxorubicin—pancreatic cancer	3.32e-05	0.000182	CcSEcCtD
Fluoxetine—Infection—Doxorubicin—pancreatic cancer	3.29e-05	0.000181	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	3.27e-05	0.000179	CcSEcCtD
Fluoxetine—Shock—Doxorubicin—pancreatic cancer	3.26e-05	0.000179	CcSEcCtD
Fluoxetine—Thrombocytopenia—Doxorubicin—pancreatic cancer	3.25e-05	0.000178	CcSEcCtD
Fluoxetine—Insomnia—Epirubicin—pancreatic cancer	3.24e-05	0.000178	CcSEcCtD
Fluoxetine—Tachycardia—Doxorubicin—pancreatic cancer	3.24e-05	0.000178	CcSEcCtD
Fluoxetine—Skin disorder—Doxorubicin—pancreatic cancer	3.22e-05	0.000177	CcSEcCtD
Fluoxetine—Paraesthesia—Epirubicin—pancreatic cancer	3.22e-05	0.000177	CcSEcCtD
Fluoxetine—Hyperhidrosis—Doxorubicin—pancreatic cancer	3.21e-05	0.000176	CcSEcCtD
Fluoxetine—Dyspnoea—Epirubicin—pancreatic cancer	3.2e-05	0.000176	CcSEcCtD
Fluoxetine—Somnolence—Epirubicin—pancreatic cancer	3.19e-05	0.000175	CcSEcCtD
Fluoxetine—Anorexia—Doxorubicin—pancreatic cancer	3.16e-05	0.000174	CcSEcCtD
Fluoxetine—Nausea—Docetaxel—pancreatic cancer	3.16e-05	0.000173	CcSEcCtD
Fluoxetine—Dyspepsia—Epirubicin—pancreatic cancer	3.16e-05	0.000173	CcSEcCtD
Fluoxetine—Decreased appetite—Epirubicin—pancreatic cancer	3.12e-05	0.000171	CcSEcCtD
Fluoxetine—Hypotension—Doxorubicin—pancreatic cancer	3.1e-05	0.00017	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Epirubicin—pancreatic cancer	3.09e-05	0.00017	CcSEcCtD
Fluoxetine—Fatigue—Epirubicin—pancreatic cancer	3.09e-05	0.00017	CcSEcCtD
Fluoxetine—Pain—Epirubicin—pancreatic cancer	3.07e-05	0.000168	CcSEcCtD
Fluoxetine—Constipation—Epirubicin—pancreatic cancer	3.07e-05	0.000168	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	3.02e-05	0.000166	CcSEcCtD
Fluoxetine—Insomnia—Doxorubicin—pancreatic cancer	3e-05	0.000165	CcSEcCtD
Fluoxetine—Paraesthesia—Doxorubicin—pancreatic cancer	2.98e-05	0.000164	CcSEcCtD
Fluoxetine—Dyspnoea—Doxorubicin—pancreatic cancer	2.96e-05	0.000162	CcSEcCtD
Fluoxetine—Feeling abnormal—Epirubicin—pancreatic cancer	2.95e-05	0.000162	CcSEcCtD
Fluoxetine—Somnolence—Doxorubicin—pancreatic cancer	2.95e-05	0.000162	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Epirubicin—pancreatic cancer	2.93e-05	0.000161	CcSEcCtD
Fluoxetine—Dyspepsia—Doxorubicin—pancreatic cancer	2.92e-05	0.00016	CcSEcCtD
Fluoxetine—Decreased appetite—Doxorubicin—pancreatic cancer	2.88e-05	0.000158	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	2.86e-05	0.000157	CcSEcCtD
Fluoxetine—Fatigue—Doxorubicin—pancreatic cancer	2.86e-05	0.000157	CcSEcCtD
Fluoxetine—Urticaria—Epirubicin—pancreatic cancer	2.85e-05	0.000156	CcSEcCtD
Fluoxetine—Pain—Doxorubicin—pancreatic cancer	2.84e-05	0.000156	CcSEcCtD
Fluoxetine—Constipation—Doxorubicin—pancreatic cancer	2.84e-05	0.000156	CcSEcCtD
Fluoxetine—Abdominal pain—Epirubicin—pancreatic cancer	2.83e-05	0.000156	CcSEcCtD
Fluoxetine—Body temperature increased—Epirubicin—pancreatic cancer	2.83e-05	0.000156	CcSEcCtD
Fluoxetine—Feeling abnormal—Doxorubicin—pancreatic cancer	2.73e-05	0.00015	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Doxorubicin—pancreatic cancer	2.71e-05	0.000149	CcSEcCtD
Fluoxetine—Hypersensitivity—Epirubicin—pancreatic cancer	2.64e-05	0.000145	CcSEcCtD
Fluoxetine—Urticaria—Doxorubicin—pancreatic cancer	2.63e-05	0.000145	CcSEcCtD
Fluoxetine—Body temperature increased—Doxorubicin—pancreatic cancer	2.62e-05	0.000144	CcSEcCtD
Fluoxetine—Abdominal pain—Doxorubicin—pancreatic cancer	2.62e-05	0.000144	CcSEcCtD
Fluoxetine—Asthenia—Epirubicin—pancreatic cancer	2.57e-05	0.000141	CcSEcCtD
Fluoxetine—Pruritus—Epirubicin—pancreatic cancer	2.54e-05	0.000139	CcSEcCtD
Fluoxetine—Diarrhoea—Epirubicin—pancreatic cancer	2.45e-05	0.000135	CcSEcCtD
Fluoxetine—Hypersensitivity—Doxorubicin—pancreatic cancer	2.44e-05	0.000134	CcSEcCtD
Fluoxetine—Asthenia—Doxorubicin—pancreatic cancer	2.38e-05	0.000131	CcSEcCtD
Fluoxetine—Dizziness—Epirubicin—pancreatic cancer	2.37e-05	0.00013	CcSEcCtD
Fluoxetine—Pruritus—Doxorubicin—pancreatic cancer	2.35e-05	0.000129	CcSEcCtD
Fluoxetine—Vomiting—Epirubicin—pancreatic cancer	2.28e-05	0.000125	CcSEcCtD
Fluoxetine—Diarrhoea—Doxorubicin—pancreatic cancer	2.27e-05	0.000125	CcSEcCtD
Fluoxetine—Rash—Epirubicin—pancreatic cancer	2.26e-05	0.000124	CcSEcCtD
Fluoxetine—Dermatitis—Epirubicin—pancreatic cancer	2.26e-05	0.000124	CcSEcCtD
Fluoxetine—Headache—Epirubicin—pancreatic cancer	2.25e-05	0.000123	CcSEcCtD
Fluoxetine—Dizziness—Doxorubicin—pancreatic cancer	2.19e-05	0.00012	CcSEcCtD
Fluoxetine—Nausea—Epirubicin—pancreatic cancer	2.13e-05	0.000117	CcSEcCtD
Fluoxetine—Vomiting—Doxorubicin—pancreatic cancer	2.11e-05	0.000116	CcSEcCtD
Fluoxetine—Rash—Doxorubicin—pancreatic cancer	2.09e-05	0.000115	CcSEcCtD
Fluoxetine—Dermatitis—Doxorubicin—pancreatic cancer	2.09e-05	0.000115	CcSEcCtD
Fluoxetine—Headache—Doxorubicin—pancreatic cancer	2.08e-05	0.000114	CcSEcCtD
Fluoxetine—Nausea—Doxorubicin—pancreatic cancer	1.97e-05	0.000108	CcSEcCtD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	3.32e-06	0.000335	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—PIK3CB—pancreatic cancer	3.27e-06	0.00033	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—PIK3CD—pancreatic cancer	3.26e-06	0.000328	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—PIK3CB—pancreatic cancer	3.23e-06	0.000325	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—STK11—pancreatic cancer	3.22e-06	0.000324	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—SLC2A2—pancreatic cancer	3.2e-06	0.000322	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—AGTR1—pancreatic cancer	3.2e-06	0.000322	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ARG2—pancreatic cancer	3.18e-06	0.00032	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—SMAD4—pancreatic cancer	3.18e-06	0.00032	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—SLC2A2—pancreatic cancer	3.17e-06	0.00032	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—STK11—pancreatic cancer	3.15e-06	0.000317	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—CXCL8—pancreatic cancer	3.15e-06	0.000317	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—STK11—pancreatic cancer	3.14e-06	0.000316	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	3.14e-06	0.000316	CbGpPWpGaD
Fluoxetine—ALB—Platelet activation, signaling and aggregation—AKT1—pancreatic cancer	3.12e-06	0.000314	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—HES1—pancreatic cancer	3.1e-06	0.000313	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—pancreatic cancer	3.07e-06	0.000309	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	3.03e-06	0.000305	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	3.03e-06	0.000305	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—CD44—pancreatic cancer	3e-06	0.000302	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	2.97e-06	0.000299	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—PIK3CB—pancreatic cancer	2.97e-06	0.000299	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—PIK3CD—pancreatic cancer	2.96e-06	0.000298	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	2.94e-06	0.000296	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	2.91e-06	0.000293	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—GLP1R—pancreatic cancer	2.9e-06	0.000292	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—GCG—pancreatic cancer	2.88e-06	0.00029	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—DPYD—pancreatic cancer	2.86e-06	0.000288	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—CXCL8—pancreatic cancer	2.86e-06	0.000288	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—PIK3CB—pancreatic cancer	2.84e-06	0.000286	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—TYMP—pancreatic cancer	2.78e-06	0.00028	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—TYMS—pancreatic cancer	2.77e-06	0.000278	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	2.76e-06	0.000278	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—SMAD4—pancreatic cancer	2.76e-06	0.000278	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—CXCL8—pancreatic cancer	2.73e-06	0.000275	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—TERT—pancreatic cancer	2.72e-06	0.000274	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—SLC2A2—pancreatic cancer	2.71e-06	0.000273	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—STK11—pancreatic cancer	2.71e-06	0.000273	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—TYMS—pancreatic cancer	2.7e-06	0.000272	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—HES1—pancreatic cancer	2.7e-06	0.000271	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—CD44—pancreatic cancer	2.7e-06	0.000271	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	2.68e-06	0.00027	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	2.64e-06	0.000266	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—CD44—pancreatic cancer	2.63e-06	0.000265	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	2.62e-06	0.000263	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—HIF1A—pancreatic cancer	2.6e-06	0.000262	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—TSC2—pancreatic cancer	2.59e-06	0.000261	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	2.59e-06	0.000261	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—SRC—pancreatic cancer	2.59e-06	0.000261	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—GCG—pancreatic cancer	2.58e-06	0.00026	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—PIK3CB—pancreatic cancer	2.58e-06	0.00026	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	2.54e-06	0.000256	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—APOE—pancreatic cancer	2.54e-06	0.000256	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—GCG—pancreatic cancer	2.52e-06	0.000254	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—VEGFA—pancreatic cancer	2.52e-06	0.000254	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—NRAS—pancreatic cancer	2.49e-06	0.000251	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—KDR—pancreatic cancer	2.49e-06	0.00025	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—CXCL8—pancreatic cancer	2.48e-06	0.00025	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—CD44—pancreatic cancer	2.48e-06	0.00025	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—CD44—pancreatic cancer	2.46e-06	0.000247	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—STK11—pancreatic cancer	2.43e-06	0.000245	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	2.41e-06	0.000242	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	2.38e-06	0.00024	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—GCG—pancreatic cancer	2.38e-06	0.000239	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—STK11—pancreatic cancer	2.37e-06	0.000239	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—NFKBIA—pancreatic cancer	2.37e-06	0.000238	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—TERT—pancreatic cancer	2.36e-06	0.000238	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	2.36e-06	0.000238	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—GCG—pancreatic cancer	2.36e-06	0.000237	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—NOTCH1—pancreatic cancer	2.34e-06	0.000236	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—TYMS—pancreatic cancer	2.33e-06	0.000234	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—TGFB1—pancreatic cancer	2.31e-06	0.000233	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PIK3CG—pancreatic cancer	2.29e-06	0.000231	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—NRAS—pancreatic cancer	2.29e-06	0.000231	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	2.28e-06	0.00023	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—EGF—pancreatic cancer	2.27e-06	0.000228	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—HIF1A—pancreatic cancer	2.26e-06	0.000227	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—TSC2—pancreatic cancer	2.25e-06	0.000227	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—APOE—pancreatic cancer	2.25e-06	0.000226	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GLP1R—pancreatic cancer	2.24e-06	0.000226	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—STK11—pancreatic cancer	2.23e-06	0.000225	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—STK11—pancreatic cancer	2.22e-06	0.000223	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—DPYD—pancreatic cancer	2.21e-06	0.000222	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—APOE—pancreatic cancer	2.21e-06	0.000222	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—APOE—pancreatic cancer	2.2e-06	0.000221	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—KDR—pancreatic cancer	2.16e-06	0.000218	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—KRAS—pancreatic cancer	2.14e-06	0.000216	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CD44—pancreatic cancer	2.1e-06	0.000211	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	2.09e-06	0.000211	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—TYMS—pancreatic cancer	2.09e-06	0.00021	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—EGFR—pancreatic cancer	2.09e-06	0.00021	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	2.08e-06	0.000209	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	2.06e-06	0.000207	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—NFKBIA—pancreatic cancer	2.05e-06	0.000207	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—TYMS—pancreatic cancer	2.04e-06	0.000205	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	2.04e-06	0.000205	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—NOTCH1—pancreatic cancer	2.03e-06	0.000205	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PIK3CG—pancreatic cancer	2.03e-06	0.000204	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PIK3CD—pancreatic cancer	2.01e-06	0.000203	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—GCG—pancreatic cancer	2.01e-06	0.000203	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—PIK3CA—pancreatic cancer	2e-06	0.000201	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PIK3CG—pancreatic cancer	1.99e-06	0.0002	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—NRAS—pancreatic cancer	1.99e-06	0.0002	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PIK3CG—pancreatic cancer	1.98e-06	0.0002	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—KRAS—pancreatic cancer	1.97e-06	0.000199	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—PIK3CA—pancreatic cancer	1.97e-06	0.000198	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—EGF—pancreatic cancer	1.97e-06	0.000198	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PPARG—pancreatic cancer	1.96e-06	0.000197	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—TYMS—pancreatic cancer	1.92e-06	0.000194	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PPARG—pancreatic cancer	1.92e-06	0.000193	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—TYMS—pancreatic cancer	1.91e-06	0.000192	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—TP53—pancreatic cancer	1.9e-06	0.000192	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—APOE—pancreatic cancer	1.89e-06	0.000191	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—STK11—pancreatic cancer	1.89e-06	0.000191	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—HRAS—pancreatic cancer	1.82e-06	0.000183	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—EGFR—pancreatic cancer	1.81e-06	0.000183	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—PIK3CA—pancreatic cancer	1.81e-06	0.000182	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	1.79e-06	0.00018	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PIK3CD—pancreatic cancer	1.78e-06	0.00018	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	1.78e-06	0.000179	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PIK3CB—pancreatic cancer	1.76e-06	0.000177	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PIK3CD—pancreatic cancer	1.75e-06	0.000176	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PIK3CD—pancreatic cancer	1.74e-06	0.000176	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—PIK3CA—pancreatic cancer	1.73e-06	0.000174	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—KRAS—pancreatic cancer	1.71e-06	0.000172	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PIK3CG—pancreatic cancer	1.71e-06	0.000172	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—APOE—pancreatic cancer	1.7e-06	0.000171	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CXCL8—pancreatic cancer	1.69e-06	0.00017	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—HRAS—pancreatic cancer	1.68e-06	0.000169	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—APOE—pancreatic cancer	1.66e-06	0.000167	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PPARG—pancreatic cancer	1.65e-06	0.000166	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—AKT1—pancreatic cancer	1.63e-06	0.000164	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—TYMS—pancreatic cancer	1.63e-06	0.000164	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CD44—pancreatic cancer	1.62e-06	0.000163	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CASP3—pancreatic cancer	1.62e-06	0.000163	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	1.61e-06	0.000162	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—AKT1—pancreatic cancer	1.61e-06	0.000162	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—PIK3CA—pancreatic cancer	1.57e-06	0.000158	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CCND1—pancreatic cancer	1.57e-06	0.000158	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—APOE—pancreatic cancer	1.56e-06	0.000157	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CTNNB1—pancreatic cancer	1.56e-06	0.000157	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PIK3CB—pancreatic cancer	1.56e-06	0.000157	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GCG—pancreatic cancer	1.55e-06	0.000156	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—APOE—pancreatic cancer	1.55e-06	0.000156	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PTGS2—pancreatic cancer	1.54e-06	0.000155	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PIK3CG—pancreatic cancer	1.53e-06	0.000154	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MMP9—pancreatic cancer	1.53e-06	0.000154	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PIK3CB—pancreatic cancer	1.52e-06	0.000154	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PIK3CB—pancreatic cancer	1.52e-06	0.000153	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PTEN—pancreatic cancer	1.52e-06	0.000153	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PTGS2—pancreatic cancer	1.51e-06	0.000152	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PIK3CD—pancreatic cancer	1.5e-06	0.000151	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PIK3CG—pancreatic cancer	1.5e-06	0.000151	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PPARG—pancreatic cancer	1.48e-06	0.000149	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—AKT1—pancreatic cancer	1.48e-06	0.000149	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	1.47e-06	0.000148	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CXCL8—pancreatic cancer	1.47e-06	0.000148	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—STK11—pancreatic cancer	1.46e-06	0.000147	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—HRAS—pancreatic cancer	1.46e-06	0.000147	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PPARG—pancreatic cancer	1.45e-06	0.000145	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—AKT1—pancreatic cancer	1.42e-06	0.000143	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	1.41e-06	0.000142	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—SRC—pancreatic cancer	1.41e-06	0.000142	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CASP3—pancreatic cancer	1.4e-06	0.000141	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PIK3CG—pancreatic cancer	1.4e-06	0.000141	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—VEGFA—pancreatic cancer	1.37e-06	0.000138	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CCND1—pancreatic cancer	1.37e-06	0.000137	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PPARG—pancreatic cancer	1.36e-06	0.000137	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—STAT3—pancreatic cancer	1.36e-06	0.000137	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—NRAS—pancreatic cancer	1.35e-06	0.000136	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CTNNB1—pancreatic cancer	1.35e-06	0.000136	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PPARG—pancreatic cancer	1.35e-06	0.000136	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PIK3CD—pancreatic cancer	1.35e-06	0.000136	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PTEN—pancreatic cancer	1.34e-06	0.000135	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MMP9—pancreatic cancer	1.33e-06	0.000133	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—APOE—pancreatic cancer	1.32e-06	0.000133	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PTEN—pancreatic cancer	1.32e-06	0.000133	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PIK3CD—pancreatic cancer	1.32e-06	0.000133	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PTEN—pancreatic cancer	1.31e-06	0.000132	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PIK3CB—pancreatic cancer	1.31e-06	0.000132	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PTGS2—pancreatic cancer	1.3e-06	0.000131	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—AKT1—pancreatic cancer	1.29e-06	0.000129	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MYC—pancreatic cancer	1.26e-06	0.000127	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—TGFB1—pancreatic cancer	1.26e-06	0.000127	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—TYMS—pancreatic cancer	1.26e-06	0.000127	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	1.25e-06	0.000126	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	1.24e-06	0.000125	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—EGFR—pancreatic cancer	1.23e-06	0.000124	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PIK3CD—pancreatic cancer	1.23e-06	0.000124	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—SRC—pancreatic cancer	1.22e-06	0.000123	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PIK3CG—pancreatic cancer	1.2e-06	0.00012	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—VEGFA—pancreatic cancer	1.19e-06	0.00012	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—STAT3—pancreatic cancer	1.18e-06	0.000119	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—NRAS—pancreatic cancer	1.18e-06	0.000118	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PIK3CB—pancreatic cancer	1.18e-06	0.000118	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—KRAS—pancreatic cancer	1.17e-06	0.000117	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PTGS2—pancreatic cancer	1.16e-06	0.000117	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PPARG—pancreatic cancer	1.15e-06	0.000116	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PIK3CB—pancreatic cancer	1.15e-06	0.000116	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PTGS2—pancreatic cancer	1.14e-06	0.000114	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PTEN—pancreatic cancer	1.13e-06	0.000114	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MYC—pancreatic cancer	1.1e-06	0.00011	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—TGFB1—pancreatic cancer	1.09e-06	0.00011	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	1.08e-06	0.000109	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PIK3CB—pancreatic cancer	1.07e-06	0.000108	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PTGS2—pancreatic cancer	1.07e-06	0.000108	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—EGFR—pancreatic cancer	1.07e-06	0.000108	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PIK3CA—pancreatic cancer	1.07e-06	0.000108	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PTGS2—pancreatic cancer	1.06e-06	0.000107	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PIK3CD—pancreatic cancer	1.05e-06	0.000106	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—TP53—pancreatic cancer	1.04e-06	0.000104	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—APOE—pancreatic cancer	1.02e-06	0.000103	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PTEN—pancreatic cancer	1.02e-06	0.000102	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—KRAS—pancreatic cancer	1.01e-06	0.000102	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PTEN—pancreatic cancer	9.91e-07	9.98e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—HRAS—pancreatic cancer	9.9e-07	9.97e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PIK3CA—pancreatic cancer	9.48e-07	9.55e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PTEN—pancreatic cancer	9.34e-07	9.41e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PIK3CA—pancreatic cancer	9.3e-07	9.36e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PIK3CA—pancreatic cancer	9.27e-07	9.33e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PTEN—pancreatic cancer	9.26e-07	9.32e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	9.22e-07	9.29e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PIK3CB—pancreatic cancer	9.16e-07	9.22e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PTGS2—pancreatic cancer	9.07e-07	9.14e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—TP53—pancreatic cancer	8.99e-07	9.05e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PPARG—pancreatic cancer	8.9e-07	8.96e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—AKT1—pancreatic cancer	8.74e-07	8.8e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—HRAS—pancreatic cancer	8.6e-07	8.66e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	8.11e-07	8.16e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PIK3CA—pancreatic cancer	7.98e-07	8.04e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PTEN—pancreatic cancer	7.91e-07	7.97e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—AKT1—pancreatic cancer	7.75e-07	7.8e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—AKT1—pancreatic cancer	7.59e-07	7.65e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—AKT1—pancreatic cancer	7.57e-07	7.62e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PIK3CA—pancreatic cancer	7.17e-07	7.21e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	7.07e-07	7.12e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PTGS2—pancreatic cancer	7e-07	7.05e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PIK3CA—pancreatic cancer	6.99e-07	7.04e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	6.59e-07	6.64e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PIK3CA—pancreatic cancer	6.53e-07	6.58e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—AKT1—pancreatic cancer	6.52e-07	6.57e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PTEN—pancreatic cancer	6.11e-07	6.15e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—AKT1—pancreatic cancer	5.85e-07	5.89e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—AKT1—pancreatic cancer	5.71e-07	5.75e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PIK3CA—pancreatic cancer	5.58e-07	5.62e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—AKT1—pancreatic cancer	5.38e-07	5.42e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—AKT1—pancreatic cancer	5.34e-07	5.37e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—AKT1—pancreatic cancer	4.56e-07	4.59e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	4.31e-07	4.34e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—AKT1—pancreatic cancer	3.52e-07	3.54e-05	CbGpPWpGaD
